Cancer Chemotherapy and Pharmacology

, Volume 67, Issue 6, pp 1211–1224 | Cite as

Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies

Mini Review



The diatomic radical nitric oxide (NO) has been the cause of intense debate with implication in carcinogenesis, tumour progression, invasion, angiogenesis and modulation of therapeutic responses. The tumour biology of NO is highly complex, and this review summarises the various protective and damaging mode of action of NO.


We reviewed all published literature addressing the complexities of the role of NO in the altered biology of cancer and evaluating promising therapeutic roles of NO/iNOS for anti-cancer therapy.


The available experimental evidences highlight contrasting pro- and anti-tumour effects of iNOS expression, which appear to be reconciled by consideration of the concentrations of NO involved, the temporo-spatial mode of NO action, intracellular targets, cellular redox state and the timing of an apoptotic stimulus. Several clinical and experimental studies indicate that the presence of NO in tumour microenvironment is detrimental to tumour cell survival and metastasis. In contrast, numerous reports suggest that NO can have tumour-promoting effects. NO is a ‘double-edged sword’ in cancer, and this review offers insight into the dichotomous nature of NO and discuss the therapeutic gain that can be achieved by manipulating tumour NO.


NO may exert a biphasic response, such that when NO levels go beyond a critical concentration that would be suitable for tumour growth and survival, growth arrest and/or apoptotic pathways are initiated. These characteristics of NO have been exploited therapeutically with impressive effects in pre-clinical models of cancer to slow tumour growth and to enhance the efficacy of both chemotherapy and radiotherapy.


Nitric oxide Nitric oxide synthase Apoptosis Radiosensitisation Bioreductive drugs and gene therapy 



Nitric oxide


Nitric oxide synthase


Tumour necrosis factor-α




Nuclear factor-κB


Hypoxia inducible factor-1


High-mobility group box 1


Mitogen-activated protein kinase


c-Jun N-terminal kinase


Vascular endothelial growth factor


  1. 1.
    Knowles RG, Moncada S (1994) Nitric oxide synthases in mammals. Biochem J 298:249–258PubMedGoogle Scholar
  2. 2.
    Nathan C, Xie QW (1994) Regulation of biosynthesis of nitric oxide. J Biol Chem 269:13725–13728PubMedGoogle Scholar
  3. 3.
    Elfering SL, Sarkela TM, Giulivi C (2002) Biochemistry of mitochondrial nitric-oxide synthase. J Biol Chem 277:38079–38086PubMedCrossRefGoogle Scholar
  4. 4.
    Schmidt HH, Walter U (1994) NO at work. Cell 78:919–925PubMedCrossRefGoogle Scholar
  5. 5.
    Hibbs JBJ (1991) Synthesis of nitric oxide from l-arginine: a recently discovered pathway induced by cytokines with antitumour and antimicrobial activity. Res Immunol 142:565–569PubMedCrossRefGoogle Scholar
  6. 6.
    Kamijo R, Harada H, Matsuyama T, Bosland M, Gerecitano J, Shapiro D, Le J, Koh SI, Kimura T, Green SJ (1994) Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 263:1612–1615PubMedCrossRefGoogle Scholar
  7. 7.
    Tendler DS, Bao C, Wang T, Huang EL, Ratovitski EA, Pardoll DA, Lowenstein CJ (2001) Intersection of interferon and hypoxia signal transduction pathways in nitric oxide-induced tumor apoptosis. Cancer Res 61:3682–3688PubMedGoogle Scholar
  8. 8.
    Melillo G, Musso T, Sica A, Taylor LS, Cox GW, Varesio LA (1995) Hypoxia responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 182:1683–1693PubMedCrossRefGoogle Scholar
  9. 9.
    Kepp O, Tesniere A, Zitvogel L, Kroemer G (2008) The immunogenicity of tumor cell death. Curr Op Oncol 21:71–76CrossRefGoogle Scholar
  10. 10.
    Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ (2010) HMGB1 and RAGE in Inflammation and Cancer. Annu Rev Immunol 28:367–388PubMedCrossRefGoogle Scholar
  11. 11.
    Taguchi A, Blood DC, del Toro G et al (2000) Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405:354–360PubMedCrossRefGoogle Scholar
  12. 12.
    Huttunen HJ, Kuja-Panula J, Sorci G et al (2000) Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 275:40096–40105PubMedCrossRefGoogle Scholar
  13. 13.
    Kuniyasu H, Chihara Y, Kondo H (2003) Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer 104:722–777PubMedCrossRefGoogle Scholar
  14. 14.
    Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S (1995) Nitric oxide synthase activity in human breast cancer. Br J Cancer 72:41–44PubMedCrossRefGoogle Scholar
  15. 15.
    Cobbs CS, Brenman JE, Aldape KD, Bredt DS, Israel MA (1995) Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 55:727–730PubMedGoogle Scholar
  16. 16.
    Masri FA, Comhair SA, Koeck T, Xu W, Janocha A, Ghosh S, Dweik RA, Golish J, Kinter M, Stuehr DJ, Erzurum SC, Aulak KS (2005) Abnormalities in nitric oxide and its derivatives in lung cancer. Am J Respir Crit Care Med 172:597–605PubMedCrossRefGoogle Scholar
  17. 17.
    Klotz T, Bloch W, Volberg C, Engelmann U, Addicks K (1998) Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer 82:1897–1903PubMedCrossRefGoogle Scholar
  18. 18.
    Lagares-Garcia JA, Moore RA, Collier B, Heggere M, Diaz F, Qian F (2001) Nitric oxide synthase as a marker in colorectal carcinoma. Am Surg 67:709–713PubMedGoogle Scholar
  19. 19.
    Hajri A, Metzger E, Vallat F, Coffy S, Flatter E, Evrard S, Marescaux J, Aprahamian M (1998) Role of nitric oxide in pancreatic tumour growth: in vivo and in vitro studies. Br J Cancer 78:841–849PubMedCrossRefGoogle Scholar
  20. 20.
    Weninger W, Rendl M, Pammer J, Mildner M, Tschugguel W, Schneeberger C, Stürzl M, Tschachler E (1998) Nitric oxide synthases in Kaposi’s sarcoma are expressed predominantly by vessels and tissue macrophages. Lab Invest 78:949–955PubMedGoogle Scholar
  21. 21.
    Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, Grimm EA (2000) Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 6:4768–4775PubMedGoogle Scholar
  22. 22.
    Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-Moreno V, Moncada S (1994) Nitric oxide synthase activity in human gynecological cancer. Cancer Res 54:1352–1354PubMedGoogle Scholar
  23. 23.
    Tschugguel W, Pustelnik T, Lass H, Mildner M, Weninger W, Schneeberger C, Jansen B, Tschachler E, Waldhör T, Huber JC, Pehamberger H (1999) Inducible nitric oxide synthase (iNOS) expression may predict distant metastasis in human melanoma. Br J Cancer 79:1609–1612PubMedCrossRefGoogle Scholar
  24. 24.
    Loibl S, von Minckwitz G, Weber S, Sinn HP, Schini-Kerth VB, Lobysheva I, Nepveu F, Wolf G, Strebhart K, Kufmann M (2002) Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopy. Cancer 95:1191–1198PubMedCrossRefGoogle Scholar
  25. 25.
    Dudzinski DM, Michel T (2007) Life history of eNOS: partners and pathways. Cardiovascular Res 75:247–260CrossRefGoogle Scholar
  26. 26.
    Vakkala M, Paakko P, Soini Y (2000) eNOS expression is associated with the estrogen and progesterone receptor status in invasive breast carcinoma. Int J Oncol 17:667–671PubMedGoogle Scholar
  27. 27.
    Zheng PP, Hop WC, Luider TM et al (2007) Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas. Ann Neurol 62:40–48PubMedCrossRefGoogle Scholar
  28. 28.
    Lim KH, Ancrile BB, Kashatus DF et al (2008) Tumour maintenance is mediated by eNOS. Nature 452:646–649PubMedCrossRefGoogle Scholar
  29. 29.
    Gosink EC, Forsberg EJ (1993) Effects of ATP and bradykinin on endothelial cell Ca2+ homeostasis and formation of cGMP and prostacyclin. Am J Physiol Cell Physiol 265:C1620–C1629Google Scholar
  30. 30.
    Ayajiki K, Kindermann M, Hecker M, Fleming I, Busse R (1996) Intracellular pH and tyrosine phosphorylation but not calcium determine shear stress-induced nitric oxide production in native endothelial cells. Circ Res 78:750–758PubMedGoogle Scholar
  31. 31.
    Wang L, Shi GG, Yao JC et al (2005) Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer. Gastric Cancer 8:18–28PubMedCrossRefGoogle Scholar
  32. 32.
    Ariel I, Hochberg A, Shochina M (1998) Endothelial nitric oxide synthase immunoreactivity in early gestation and in trophoblastic disease. J Clin Pathol 51:427–431PubMedCrossRefGoogle Scholar
  33. 33.
    Bauer PM, Fulton D, Boo YC, Sorescu GP, Kemp BE, Jo H et al (2003) Compensatory phosphorylation and protein–protein interactions revealed by loss of function and gain of function mutants of multiple serine phosphorylation sites in endothelial nitric oxide synthase. J Biol Chem 278:14841–14849PubMedCrossRefGoogle Scholar
  34. 34.
    Dudzinski DM, Igarashi J, Greif D, Michel T (2006) The regulation and pharmacology of endothelial nitric oxide synthase. Annu Rev Pharmacol Toxicol 46:235–276PubMedCrossRefGoogle Scholar
  35. 35.
    Michell BJ, Chen ZZ, Tiganis T, Stapleton D, Katsis F et al (2001) Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem 276:17625–17628PubMedCrossRefGoogle Scholar
  36. 36.
    Duda DG, Fukumura D, Jain RK (2004) Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med 10:143–145PubMedCrossRefGoogle Scholar
  37. 37.
    Chinje E, Stratford IJ (1997) The role of nitric oxide in growth of solid tumours: a balancing act. Essays Biochem 32:61–72PubMedGoogle Scholar
  38. 38.
    Lincoln TM, Dey N, Sellak HH (2001) cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol 91:1421–1430PubMedGoogle Scholar
  39. 39.
    Brunori M, Giuffre A, Forte E, Mastronicola D, Barone MC, Sarti P (2004) Control of cytochrome c oxidase activity by nitric oxide. Biochim Biophys Acta 1655:365–371PubMedCrossRefGoogle Scholar
  40. 40.
    Thomas DD, Liu X, Kantrow SP, Lancaster JR Jr (2001) The biological lifetime of nitric oxide: implications for the perivascular dynamics of NO and O2. Proc Natl Acad Sci (USA) 98:355–360CrossRefGoogle Scholar
  41. 41.
    Cooper CE, Giulivi C (2007) Nitric oxide regulation of mitochondrial oxygen consumption II: molecular mechanism and tissue physiology. Am J Physiol Cell Physiol 292:C1993–C2003PubMedCrossRefGoogle Scholar
  42. 42.
    Stuehr DJ, Santolini J, Wang ZQ, Wei CC, Adak S (2004) Update on mechanism and catalytic regulation in the NO synthases. J Biol Chem 279:36167–36170PubMedCrossRefGoogle Scholar
  43. 43.
    Ridnour LA, Thomas DD, Donzelli S, Espey MG, Roberts DD, Wink DA, Isenberg JS (2006) The biphasic nature of nitric oxide responses in tumor biology. Antioxid Red Signal 8:1329–1337CrossRefGoogle Scholar
  44. 44.
    Leon L, Jeannin J-F, Bettaieb A (2008) Post-translational modifications induced by nitric oxide (NO): implication in cancer cells apoptosis. Nitric Oxide 19:77–83PubMedCrossRefGoogle Scholar
  45. 45.
    Park HS, Yu JW, Cho JH, Kim MS, Huh SH, Ryoo K, Choi EJ (2004) Inhibition of apoptosis signal-regulating kinase 1 by nitric oxide through a thiol redox mechanism. J Biol Chem 279:7584–7590PubMedCrossRefGoogle Scholar
  46. 46.
    Sumbayev VV (2003) S-nitrosylation of thioredoxin mediates activation of apoptosis signal-regulating kinase 1. Arch Biochem Biophys 415:133–136PubMedCrossRefGoogle Scholar
  47. 47.
    DelaTorre A, Schroeder RA, Kuo PC (1997) Alteration of NF-kappa B p50 DNA binding kinetics by S-nitrosylation. Biochem Biophy Res Comm 238:703–706CrossRefGoogle Scholar
  48. 48.
    Gopalakrishna R, Chen ZH, Gundimeda U (1993) Nitric oxide and nitric oxide generating agents induce a reversible inactivation of protein kinase C activity and phorbol ester binding. J Biol Chem 268:27180–27185PubMedGoogle Scholar
  49. 49.
    Park HS, Huh SH, Kim MS, Lee SH, Choi EJ (2000) Nitric oxide negatively regulates c-Jun N-terminal kinase/stress-activated protein kinase by means of S-nitrosylation. Proc Natl Acad Sci 97:14382–14387PubMedCrossRefGoogle Scholar
  50. 50.
    Teng KK, Esposito DK, Schwartz GD, Lander HM, Hempstead BL (1999) Activation of c-Ha-Ras by nitric oxide modulates survival responsiveness in neuronal PC12 cells. J Biol Chem 274:37315–37320PubMedCrossRefGoogle Scholar
  51. 51.
    Xu L, Eu JP, Meissner G, Stamler JS (1998) Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science 279:234–237PubMedCrossRefGoogle Scholar
  52. 52.
    MacMillan-Crow LA, Greendorfer JS, Vickers SM, Thompson JA (2000) Tyrosine nitration of c-SRC tyrosine kinase in human pancreatic ductal adenocarcinoma. Arch Biochem Biophys 377:350–356PubMedCrossRefGoogle Scholar
  53. 53.
    West MB, Hill BG, Xuan YT, Bhatnagar A (2006) Protein glutathiolation by nitric oxide: an intracellular mechanism regulating redox protein modification. FASEB J 20:1715–1717PubMedCrossRefGoogle Scholar
  54. 54.
    Maulik D, Ashraf QM, Mishra OP, Delivoria-Papadopoulos M (2008) Activation of p38 mitogen-activated protein kinase (p38 MAPK), extracellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK) during hypoxia in cerebral cortical nuclei of guinea pig fetus at term: role of nitric oxide. Neurosci Lett 439:94–99PubMedCrossRefGoogle Scholar
  55. 55.
    Lander HM, Ogiste JS, Pearce SF, Levi R, Novogrodsky A (1995) Nitric oxide stimulated guanine nucleotide exchange on p21ras. J Biol Chem 270:7017–7020PubMedCrossRefGoogle Scholar
  56. 56.
    Duhé RJ, Evans GA, Erwin RA, Kirken RA, Cox GW, Farrar WL (1998) Nitric oxide and thiol redox regulation of Janus kinase activity. Proc Natl Acad Sci 95:126–131PubMedCrossRefGoogle Scholar
  57. 57.
    Tejedo JR, Cahuana GM, Ramirez R, Esbert M, Jiménez J, Sobrino F, Bedoya FJ (2004) Nitric oxide triggers the phosphatidylinositol 3-kinase/Akt survival pathway in insulin-producing RINm5F cells by arousing Src to activate insulin receptor substrate-1. Endocrinology 145:2319–2327PubMedCrossRefGoogle Scholar
  58. 58.
    Lander HM, Jacovina AT, Davis RJ, Tauras JM (1996) Differential activation of mitogen-activated protein kinases by nitric oxide-related species. J Biol Chem 271:19705–19709PubMedCrossRefGoogle Scholar
  59. 59.
    Lala PK, Chakraborty C (2001) Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2:149–156PubMedCrossRefGoogle Scholar
  60. 60.
    Pervin S, Singh R, Chaudhuri G (2008) Nitric Oide, Nω-hydroxy-l-arginine and breast cancer. Nitric Oxide 19:103–106PubMedCrossRefGoogle Scholar
  61. 61.
    Thomas DD, Espey MG, Ridnour LA, Hofseth LJ, Mancardi D, Harris CC, Wink DA (2004) Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci 101:8894–8899PubMedCrossRefGoogle Scholar
  62. 62.
    Pervin S, Singh R, Hernandez E, Wu G, Chaudhuri G (2007) Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway. Cancer Res 67:289–299PubMedCrossRefGoogle Scholar
  63. 63.
    Schonhoff CM, Gaston B, Mannick JB (2003) Nitrosylation of cytochrome c during apoptosis. J Biol Chem 278:18265–18270PubMedCrossRefGoogle Scholar
  64. 64.
    Millet A, Bettaieb A, Renaud F, Prevotat L, Hammann A, Solary E, Mignotte B, Jeannin JF (2002) Influence of the nitric oxide donor glyceryl trinitrate on apoptotic pathways in human colon cancer cells. Gastroenterology 123:235–246PubMedCrossRefGoogle Scholar
  65. 65.
    Mannick JB, Schonhoff C, Papeta N, Ghafourifar P, Szibor M, Fang K, Gaston B (2001) S-Nitrosylation of mitochondrial caspases. J Cell Biol 154:1111–1116PubMedCrossRefGoogle Scholar
  66. 66.
    Iyer AKV, Azad N, Wang L, Rojanasakul Y (2008) Role of S-nitrosylation in apoptosis resistance and angiogenesis. Nitric Oxide 19:146–151PubMedCrossRefGoogle Scholar
  67. 67.
    Cook T, Wang Z, Alber S, Liu K, Watkins SC, Vodovotz Y, Billiar TR, Blumberg D (2004) Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53. Cancer Res 64:8015–8021PubMedCrossRefGoogle Scholar
  68. 68.
    Zhang Y, Xiong Y (2001) A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science 292:1910–1915PubMedCrossRefGoogle Scholar
  69. 69.
    Wang X, Zalcenstein A, Oren M (2003) Nitric oxide promotes p53 nuclear retention and sensitizes neuroblastoma cells to apoptosis by ionizing radiation. Cell Death Differ 10:468–476PubMedCrossRefGoogle Scholar
  70. 70.
    Yakovlev VA, Bayden AS, Graves PR, Kellogg GE, Mikkelsen RB (2010) Nitration of the tumor suppressor protein p53 at tyrosine 327 promotes p53 oligomerization and activation. Biochemistry 49:5331–5339PubMedCrossRefGoogle Scholar
  71. 71.
    Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, Jhappan C, Higashimoto Y, He P, Linke SP, Quezado MM, Zurer I, Rotter V, Wink DA, Appella E, Harris CC (2003) Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci 1000:143–148CrossRefGoogle Scholar
  72. 72.
    Cobbs CS, Samanta M, Harkins LE, Gillespie GY, Merrick BA, MacMillan-Crow LA (2001) Evidence for peroxynitrite-mediated modifications to p53 in human gliomas: possible functional consequences. Arch Biochem Biophys 394:167–172PubMedCrossRefGoogle Scholar
  73. 73.
    Xu W, Liu L, Smith GC, Charles IG (2000) Nitric oxide upregulates expression of DNA-PKcs to protect cells from DNA-damaging anti-tumour agents. Nat Cell Biol 2:339–345PubMedCrossRefGoogle Scholar
  74. 74.
    Jones MK, Tsugawa K, Tarnawski AS, Baatar D (2004) Dual actions of nitric oxide on angiogenesis: possible roles of PKC, ERK, and AP-1. Biochem Biophys Res Comm 318:520–528PubMedCrossRefGoogle Scholar
  75. 75.
    Pervin S, Singh R, Freije WA, Chaudhuri G (2003) MKP-1-induced dephosphorylation of extracellular signal-regulated kinase is essential for triggering nitric oxide-induced apoptosis in human breast cancer cell lines: implications in breast cancer. Cancer Res 63:8853–8860PubMedGoogle Scholar
  76. 76.
    Chao JI, Kuo PC, Hsu TS (2004) Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem 279:20267–20276PubMedCrossRefGoogle Scholar
  77. 77.
    Garbán HJ, Bonavida B (2001) Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. J Immunol 167:75–81PubMedGoogle Scholar
  78. 78.
    Garbán HJ, Bonavida B (2001) Nitric oxide disrupts H2O2-dependent activation of nuclear factor kappa B. role in sensitization of human tumor cells to tumor necrosis factor-alpha-induced cytotoxicity. J Biol Chem 276:8918–8923PubMedCrossRefGoogle Scholar
  79. 79.
    Tozer GM, Prise VE, Chaplin DJ (1997) Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with l-arginine. Cancer Res 57:948–955PubMedGoogle Scholar
  80. 80.
    Ishii Y, Ogura T, Tatemichi M, Fujisawa H, Otsuka F, Esumi H (2003) Induction of matrix metalloproteinase gene transcription by nitric oxide and mechanisms of MMP-1 gene induction in human melanoma cell lines. Int J Cancer 103:161–168PubMedCrossRefGoogle Scholar
  81. 81.
    Wu J, Akaike T, Hayashida K, Okamoto T, Okuyama A, Maeda H (2001) Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. Jpn J Cancer Res 92:439–451PubMedGoogle Scholar
  82. 82.
    Aurello P, Rossi Del Monte S, D’Angelo F, Cicchini C, Ciardi A, Bellagamba R, Ravaioli M, Ramacciato G (2009) Vascular endothelial growth factor C and microvessel density in gastric carcinoma: correlation with clinicopathological factors. Our experience and review of the literature. Oncol Res 17:405–411PubMedCrossRefGoogle Scholar
  83. 83.
    Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Tsukiyama A, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K (2003) Clinicopathological significance of vascular endothelial growth factor-C in breast carcinoma with long-term follow-up. Mod Pathol 16:309–314PubMedCrossRefGoogle Scholar
  84. 84.
    Ichinoe M, Mikami T, Shiraishi H, Okayasu I (2004) High microvascular density is correlated with high VEGF, iNOS and COX-2 expression in penetrating growth-type early gastric carcinomas. Histopathology 45:612–618PubMedCrossRefGoogle Scholar
  85. 85.
    Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB III (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200. J Clin Oncol 25:1539–1544PubMedCrossRefGoogle Scholar
  86. 86.
    Cahlin C, Gelin J, Delbro D, Lönnroth C, Doi C, Lundholm K (2000) Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids. Cancer Res 60:1742–1749PubMedGoogle Scholar
  87. 87.
    Radomski MW, Jenkins DC, Holms L, Moncada S (1991) Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Res 51:6073–6078PubMedGoogle Scholar
  88. 88.
    Dong Z, Staroselsky AH, Qi X, Xie K, Fidler IJ (1994) Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murine melanoma cells. Cancer Res 54:789–793PubMedGoogle Scholar
  89. 89.
    Xie K, Huang S, Dong Z, Juang SH, Gutman M, Xie QW, Nathan C, Fidler IJ (1995) Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 181:1333–1343PubMedCrossRefGoogle Scholar
  90. 90.
    Le X, Wei D, Huang S, Lancaster JR Jr, Xie K (2005) Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its upregulation of protumor factors. Proc Natl Acad Sci 102:8758–8763PubMedCrossRefGoogle Scholar
  91. 91.
    Kiziltepe T, Hideshima T, Ishitsuka K, Ocio EM, Raje N, Catley L, Li C-Q, Trudel LJ, Yasui H, Vallet S, Kutok JL, Chauhan D, Mitsiades CS, Saavedra JE, Wogan GN, Keefer LK, Shami PJ, Anderson KC (2007) JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood 110:709–718PubMedCrossRefGoogle Scholar
  92. 92.
    Postovit LM, Adams MA, Lash GE, Heaton JP, Graham CH (2004) Nitric oxide-mediated regulation of hypoxia-induced B16F10 melanoma metastasis. Int J Cancer 108:47–53PubMedCrossRefGoogle Scholar
  93. 93.
    Konovalova NP, Goncharova SA, Volkova LM, Rajewskaya TA, Eremenko LT, Korolev AM (2003) Nitric oxide donor increases the efficiency of cytostatic therapy and reatrds the development of drug resistance. Nitric Oxide 8:59–64PubMedCrossRefGoogle Scholar
  94. 94.
    Riganti C, Miraglia E, Viarisio D, Costamagna C, Pescarmona G, Ghigo D, Bosia A (2005) Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res 65:516–525PubMedGoogle Scholar
  95. 95.
    Muir CP, Adams MA, Graham CH (2006) Nitric oxide attenuates resistance to doxorubicin in three-dimensional aggregates of human breast carcinoma cells. Breast Cancer Res Treat 96:169–176PubMedCrossRefGoogle Scholar
  96. 96.
    Cook JA, Krishna MC, Pacelli R, DeGraff W, Liebmann J, Mitchell JB, Russo A, Wink DA (1997) Nitric oxide enhancement of melphalan-induced cytotoxicity. Br J Cancer 76:325–334PubMedCrossRefGoogle Scholar
  97. 97.
    Adams DJ, Levesque MC, Weinberg JB, Smith KL, Flowers JL, Moore J, Colvin OM, Silber R (2001) Nitric oxide enhancement of fludarabine cytotoxicity for BCLL lymphocytes. Leukemia 15:1852–1859PubMedGoogle Scholar
  98. 98.
    Yasuda H, Yamaya M, Nakayama K, Sasaki T, Ebihara S, Kanda A, Asada M, Inoue D, Suzuki T, Okazaki T, Takahashi H, Yoshida M, Kaneta T, Ishizawa K, Yamanda S, Tomita N, Yamasaki M, Kikuchi A, Kubo H, Sasaki H (2006) Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 24:688–694PubMedCrossRefGoogle Scholar
  99. 99.
    Huang LE, Bindra RS, Glazer PM, Harris AL (2007) Hypoxia-induced genetic instability-a calculated mechanism underlying tumor progression. J Mol Med 85:139–148PubMedCrossRefGoogle Scholar
  100. 100.
    Brown JM (1999) The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 59:5863–5870PubMedGoogle Scholar
  101. 101.
    Sandau KB, Fandrey J, Brune B (2001) Accumulation of HIF-1alpha under the influence of nitric oxide. Blood 97:1009–1015PubMedCrossRefGoogle Scholar
  102. 102.
    Metzen E, Zhou J, Jelkmann W, Fandrey J, Brune B (2003) Nitric oxide impairs normoxic degradation of HIF-1α by inhibition of prolyl hydroxylases. Mol Biol Cell 14:3470–3481PubMedCrossRefGoogle Scholar
  103. 103.
    Mateo J, Garcia-Lecea M, Cadenas S, Hernandez C, Moncada S (2003) Regulation of hypoxia-inducible factor-1alpha by nitric oxide through mitochondria-dependent and -independent pathways. Biochem J 376:537–544PubMedCrossRefGoogle Scholar
  104. 104.
    Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4:437–447PubMedCrossRefGoogle Scholar
  105. 105.
    McKeown SR, Cowen RL, Williams KJ (2007) Bioreductive drugs: from concept to clinic. Clin Oncol 19:427–442CrossRefGoogle Scholar
  106. 106.
    Peters KB, Brown JM (1993) Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res 62:5248–5253Google Scholar
  107. 107.
    Chinje EC, Cowen RL, Feng J, Sharma SP, Wind NS, Harris AL, Stratford IJ (2003) Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro. Mol Pharmacol 63:1248–1255PubMedCrossRefGoogle Scholar
  108. 108.
    Patterson LH (1993) Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metastasis Rev 12:119–134PubMedCrossRefGoogle Scholar
  109. 109.
    Cowen RL, Singh S, Chinje EC, Al-Assah R, Harris P, Dunk C, Stratford IJ (2005) Adenoviral delivery of inducible nitric oxide synthase (NOSII) enhances AQ4 N/radiation cytotoxicity within hypoxic tumor cells. AACR Meeting Abstracts 314-AGoogle Scholar
  110. 110.
    Robson T, Worthington J, McKeown SR, Hirst DG (2005) Radiogenic therapy: novel approaches for enhancing tumor radiosensitivity. Technol Cancer Res Treat 4:343–361PubMedGoogle Scholar
  111. 111.
    Gray LH, Green FO, Hawes CA (1958) Effect of nitric oxide on the radiosensitivity of tumour cells. Nature 182:952–953PubMedCrossRefGoogle Scholar
  112. 112.
    Mitchell JB, Wink DA, DeGraff W, Gamson J, Keefer LK, Krishna MC (1993) Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res 53:5845–5848PubMedGoogle Scholar
  113. 113.
    Verovski VN, Van den Berge DL, Soete GA, Bols BL, Storme GA (1996) Intrinsic radiosensitivity of human pancreatic tumour cells and the radiosensitising potency of the nitric oxide donor sodium nitroprusside. Br J Cancer 74:1734–1742PubMedCrossRefGoogle Scholar
  114. 114.
    Wardman P, Rothkamm K, Folkes LK, Woodcock M, Johnston PJ (2007) Radiosensitization by nitric oxide at low radiation doses. Radiat Res 167:475–484PubMedCrossRefGoogle Scholar
  115. 115.
    Singh S, Cowen RL, Chinje EC, Stratford IJ (2009) The impact of intracellular generation of nitric oxide on the radiation response of human tumor cells. Radiat Res 171:572–580PubMedCrossRefGoogle Scholar
  116. 116.
    Li F, Sonveaux P, Rabbani ZN, Liu S, Yan B, Huang Q, Vujaskovic Z, Dewhirst MW, Li CY (2007) Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell 26:63–74PubMedCrossRefGoogle Scholar
  117. 117.
    Abrams J (1992) Mechanisms of action of the organic nitrates in the treatment of myocardial ischemia. Am J Cardiol 70:30B–42BPubMedCrossRefGoogle Scholar
  118. 118.
    Soler MN, Bobe P, Benihoud K, Lemaire G, Roos BA, Lausson S (2000) Gene therapy of rat medullary thyroid cancer by naked nitric oxide synthase II DNA injection. J Gene Med 2:344–352PubMedCrossRefGoogle Scholar
  119. 119.
    Wang Z, Cook T, Alber S, Liu K, Kovesdi I, Watkins SK, Vodovotz Y, Billiar TR, Blumberg D (2004) Adenoviral gene transfer of the human inducible nitric oxide synthase gene enhances the radiation response of human colorectal cancer associated with alterations in tumor vascularity. Cancer Res 64:1386–1395PubMedCrossRefGoogle Scholar
  120. 120.
    Worthington J, McCarthy HO, Barrett E, Adams C, Robson T, Hirst DG (2004) Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment. J Gene Med 6:673–680PubMedCrossRefGoogle Scholar
  121. 121.
    Halliwill JR, Minson CT, Joyner MJ (2000) Effect of systemic nitric oxide synthase inhibition on postexercise hypotension in humans. J Appl Physiol 89:1830–1836PubMedGoogle Scholar
  122. 122.
    Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG (2002) The role of nitric oxide in cancer. Cell Res 12:311–320PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Department of Biotechnology, School of Engineering and TechnologySharda UniversityGreater Noida, Gautam Budha NagarIndia
  2. 2.Institute of Integrative BiologySwiss Federal Institute of Technology (ETH)ZurichSwitzerland

Personalised recommendations